GGHC
ACAD icon

Gilder Gagnon Howe & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,022
Closed -$135K – 278
2018
Q1 		$135K Sell
6,022
-106,604
-95% -$2.95M ﹤0.01% 268
2017
Q4 		$3.39M Sell
112,626
-10,545
-9% -$337K 0.05% 180
2017
Q3 		$4.64M Buy
123,171
+111,982
+1,001% +$3.64M 0.07% 151
2017
Q2 		$312K Buy
11,189
+2,243
+25% +$66.8K ﹤0.01% 232
2017
Q1 		$308K Buy
8,946
+7,975
+821% +$282K 0.01% 228
2016
Q4 		$28K Sell
971
-4,658
-83% -$123K ﹤0.01% 258
2016
Q3 		$179K Buy
5,629
+990
+21% +$33.6K ﹤0.01% 233
2016
Q2 		$151K Sell
4,639
-32
-0.7% -$1.07K ﹤0.01% 237
2016
Q1 		$131K Sell
4,671
-134,363
-97% -$2.93M ﹤0.01% 207
2015
Q4 		$4.96M Sell
139,034
-168,797
-55% -$5.95M 0.08% 122
2015
Q3 		$10.2M Sell
307,831
-3,353
-1% -$140K 0.16% 100
2015
Q2 		$13M Sell
311,184
-6,051
-2% -$234K 0.17% 93
2015
Q1 		$10.3M Sell
317,235
-1,357,327
-81% -$46.7M 0.14% 101
2014
Q4 		$53.2M Sell
1,674,562
-14,327
-0.8% -$406K 0.79% 39
2014
Q3 		$41.8M Sell
1,688,889
-23,164
-1% -$542K 0.61% 48
2014
Q2 		$38.7M Sell
1,712,053
-397,311
-19% -$8.29M 0.51% 51
2014
Q1 		$51.3M Buy
2,109,364
+49,835
+2% +$1.26M 0.7% 47
2013
Q4 		$51.5M Buy
2,059,529
+380,353
+23% +$8.97M 0.73% 40
2013
Q3 		$46.1M Sell
1,679,176
-26,332
-2% -$550K 0.72% 46
2013
Q2 		$31M Buy
+1,705,508
New +$23.5M 0.58% 53

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Gilder Gagnon Howe & Co's ACAD Position: Q2 2018 in Review

Gilder Gagnon Howe & Co sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 6,022 shares — an estimated $135K sold.

Gilder Gagnon Howe & Co first reported a position in ACAD in Q2 2013 and held it in 20 quarters. The position peaked at $53.2M in Q4 2014. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

  • Gilder Gagnon Howe & Co reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 6,022 Acadia Pharmaceuticals shares in Q2 2018, an estimated $135K.
  • Gilder Gagnon Howe & Co first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 20 quarters.
  • Gilder Gagnon Howe & Co's Acadia Pharmaceuticals position peaked at $53.2M in Q4 2014.
  • 187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2018, filed 31 Jul 2018.